Journal of the National Comprehensive Cancer Network

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Monday, November 6, 2023
Bristol Myers Squibb, Research, National Comprehensive Cancer Network, PD-L1, Colorectal cancer, Trial of the century, NSCLC, ESMO, MAA, CHMP, Therapy, Life, Committee, Pembrolizumab, European Directive on Traditional Herbal Medicinal Products, Docetaxel, Contingent value rights, Acquisition, Committee for Medicinal Products for Human Use, Conditional, Journal of the National Comprehensive Cancer Network, Cetuximab, MHRA, Marketing, EMA, NCCN, European Medicines Agency, Immunotherapy, Colon, Lung cancer, Medicines and Healthcare products Regulatory Agency, European Society for Medical Oncology, Cancer, Investment, CVR, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry, Nursing, Mirati

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
  • We look forward to continuing our work to improve the lives of people with cancer through Mirati discovered and developed therapeutics."
  • Excluding the August 2023 financing, net decrease in cash, cash equivalents and short-term investments for the third quarter of 2023 was $135.5 million.
  • Net KRAZATI product revenue for the three and nine months ended September 30, 2023 was $16.4 million and $36.1 million, respectively.

NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer

Retrieved on: 
Monday, October 30, 2023
Patient, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Gold, Policy, Weather, NCI, Publishing, Visit, Health, Fatigue, Cancer-related fatigue, Vomiting, Doctor of Philosophy, Palliative care, Nausea, Quality of life, University of Wisconsin Carbone Cancer Center, Caregiver, Disease, Medicine, National Cancer Institute, NCCN, University, Anschutz Medical Campus, Anemia, Diagnosis, Book, MS, Pharmaceutical industry, Nursing, Medical device, Residential care, Medical imaging, MD, Cancer

PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing new resources focused on improving quality of life for people with cancer while making sure care planning reflects individual needs and priorities. Today marks the publication of a new NCCN Guidelines for Patients®: Palliative Care, part of an ongoing expansion of supportive care resources. The new NCCN Guidelines for Patients: Fatigue and Cancer is also publishing, along with an updated book on managing Distress During Cancer Care.

Key Points: 
  • Today marks the publication of a new NCCN Guidelines for Patients®: Palliative Care , part of an ongoing expansion of supportive care resources.
  • The new NCCN Guidelines for Patients: Fatigue and Cancer is also publishing, along with an updated book on managing Distress During Cancer Care .
  • All guides are available free-of-charge at NCCN.org/patientguidelines or via the NCCN Patient Guides for Cancer App .
  • Dr. Campbell stressed that palliative care is an important part of comprehensive cancer care regardless of age, cancer stage, or the need for other therapies.

NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer

Retrieved on: 
Monday, October 30, 2023
Patient, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Gold, Policy, Weather, NCI, Publishing, Visit, Health, Fatigue, Cancer-related fatigue, Vomiting, Doctor of Philosophy, Palliative care, Nausea, Quality of life, University of Wisconsin Carbone Cancer Center, Caregiver, Disease, Medicine, National Cancer Institute, NCCN, University, Anschutz Medical Campus, Anemia, Diagnosis, Book, MS, Pharmaceutical industry, Nursing, Medical device, Residential care, Medical imaging, MD, Cancer

PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is announcing new resources focused on improving quality of life for people with cancer while making sure care planning reflects individual needs and priorities. Today marks the publication of a new NCCN Guidelines for Patients®: Palliative Care, part of an ongoing expansion of supportive care resources. The new NCCN Guidelines for Patients: Fatigue and Cancer is also publishing, along with an updated book on managing Distress During Cancer Care.

Key Points: 
  • Today marks the publication of a new NCCN Guidelines for Patients®: Palliative Care , part of an ongoing expansion of supportive care resources.
  • The new NCCN Guidelines for Patients: Fatigue and Cancer is also publishing, along with an updated book on managing Distress During Cancer Care .
  • All guides are available free-of-charge at NCCN.org/patientguidelines or via the NCCN Patient Guides for Cancer App .
  • Dr. Campbell stressed that palliative care is an important part of comprehensive cancer care regardless of age, cancer stage, or the need for other therapies.

More Aggressive Treatment Doesn't Impact Quality of Life for Metastatic Colorectal Cancer Patients, According to New Study in JNCCN

Retrieved on: 
Thursday, October 12, 2023
Neoplasm, Quality of life, CAPOX, Max Healthcare, Penn Medicine Princeton Medical Center, Bevacizumab, Risk, Radiation, EORTC, SAE, Șaeș, Survival, Outline of health sciences, University, Disease, FOLFOX, Patient, Quality of life (healthcare), FACP, University of Pennsylvania Health System, Fatigue, Medicine, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Overalls, Face, Perelman Center for Advanced Medicine, Research, Pharmaceutical industry, Nursing, Medical imaging, Life, MD

PLYMOUTH MEETING, Pa., Oct. 12, 2023 /PRNewswire/ -- New research in the October 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

Key Points: 
  • Significant adverse events were reported in 21% of patients in the standard group and 43% of patients who also received tumor debulking.
  • However, there were no statistical or clinically relevant differences according to patient-reported outcomes for overall health-related quality of life or fatigue.
  • "This could mean that the negative impact of complications on quality of life is temporary and eventually balances out with a decrease in tumor-related symptoms after treatment.
  • "Given the considerable amount of complications from local treatment, we had expected to see a bigger impact on overall and persistent quality of life in the experimental group.

CAP Molecular Proficiency Testing Programs Demonstrate Accurate Clinical Cancer Sequencing Results

Retrieved on: 
Monday, October 2, 2023
Medical Supplies, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, NRAS, KRAS, Sustainability, CAP, NGS, Policy, National Comprehensive Cancer Network, Journal of the National Comprehensive Cancer Network, RAS, Patient, Laboratory, Colorectal cancer, Therapy, Gene, Medical device, Medical imaging, MD

“This reanalysis indicates that patients undergoing molecular testing at laboratories using CAP PT can continue to be confident that their test results are accurate,” explained CAP President Emily E. Volk, MD, FCAP.

Key Points: 
  • “This reanalysis indicates that patients undergoing molecular testing at laboratories using CAP PT can continue to be confident that their test results are accurate,” explained CAP President Emily E. Volk, MD, FCAP.
  • Testing for RAS mutations is recommended by the National Comprehensive Cancer Network for advanced or metastatic colorectal cancer to determine eligibility for anti-EGFR therapy.
  • The study’s conclusions extrapolated results to all molecular testing, even though they did not reflect real world scenarios.
  • “Furthermore, given the robust evidence of strong testing performance in clinical laboratories using CAP PT programs, there is no meaningful benefit for additional assessment from a third party on the performance of molecular testing in these laboratories.”

NCCN Senior Director Evelyn Handel Zapata is Named a '40 Under 40 in Cancer: Emerging Leader' for Milestone Work Improving Safe Use of Chemotherapy

Retrieved on: 
Monday, September 25, 2023
BCPS, Doctor of Pharmacy, Fred Hutchinson Cancer Research Center, BeiGene, HOPA, Journal of the National Comprehensive Cancer Network, Pharmacy, HIT, NCCN, Pharmacist, MD, Swim Across America, International Society, Safety, American Society of Pediatric Hematology/Oncology, Medical device, Pharmaceutical industry, Nursing, Takeda, Drug, Cancer

PLYMOUTH MEETING, Pa., Sept. 25, 2023 /PRNewswire/ -- Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader at a national reception in Chicago in June. This achievement comes as the NCCN Chemotherapy Order Templates (NCCN Templates®) program celebrates its 15th anniversary and launches new resources for a type of pediatric lymphoma today.

Key Points: 
  • PLYMOUTH MEETING, Pa., Sept. 25, 2023 /PRNewswire/ -- Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader at a national reception in Chicago in June.
  • This achievement comes as the NCCN Chemotherapy Order Templates ( NCCN Templates ®) program celebrates its 15th anniversary and launches new resources for a type of pediatric lymphoma today.
  • "Evelyn's work at NCCN has helped advance pharmacist involvement... on important national guidelines."
  • 40 Under 40 in Cancer is an awards initiative that recognizes contributions being made across the field of cancer by rising stars and emerging leaders under the age of 40.

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

Retrieved on: 
Thursday, September 21, 2023
Research, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, General Health, Health, Science, Oncology, Other Science, Central nervous system, University, Spinal cord, Journal of the National Comprehensive Cancer Network, Cancer, Quality of life, Breast, Brain, NSCLC, Cerebrospinal fluid, Doctor of Philosophy, CNS, Terminal, Membrane, MRI, MD, Physician, Patient, University of Washington School of Medicine, LM, Neoplasm, Neuro, Medical imaging

The FORESEE trial is specifically designed to measure the impact of CNSide on physicians’ clinical decisions to generate the data needed to help us reach this goal.

Key Points: 
  • The FORESEE trial is specifically designed to measure the impact of CNSide on physicians’ clinical decisions to generate the data needed to help us reach this goal.
  • CNSide has notable advantages over current standards of care, such as cytology, clinical evaluation and MRI, which have limited sensitivity and specificity.
  • “The current standards of care can present a significant obstacle in patient care due to the limitations in the detection and monitoring of LM.
  • Enrollment is currently open at four clinical sites with two additional sites expected to join the FORESEE trial in the near term.

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Retrieved on: 
Friday, September 8, 2023
Research, Medical Devices, FDA, Clinical Trials, Radiology, Health, Pharmaceutical, Science, Oncology, Melanoma, Central nervous system, Plus Therapeutics, Spinal cord, Food and Drug Administration, Clinical trial, Cancer, Brain, Cerebrospinal fluid, Rhenium, CNS, Membrane, Journal of the National Comprehensive Cancer Network, Gold, Patient, LM, PSTV, Diagnosis, CSF, Therapy, Carcinoma, Technology transfer, Food, Pharmaceutical industry

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022.
  • This new agreement allows for Plus to perform CNSide testing during its clinical trials and commercially, subject to regulatory approval.
  • Once the technology transfer is complete, Plus will pay Biocept $300,000 plus fees on a sliding scale starting at $2,800 for each CNSide test they perform.
  • The license agreement also gives Plus the option to negotiate for third-party exclusivity with a $1,000,000 payment to Biocept.

New Resource from National Comprehensive Cancer Network Breaks the Silence on Common but Lesser-Known Cause of Cancer Deaths

Retrieved on: 
Thursday, September 7, 2023
Pancreatic cancer, Sidney Kimmel, VTE, Surgeon, Thrombus, Journal of the National Comprehensive Cancer Network, Pulmonary embolism, Neoplasm, Multiple myeloma, Graft-versus-host disease, Risk assessment, Chest pain, National Comprehensive Cancer Network, Thrombosis, Cardiology, Immunotherapy, Visit, NCCN, Radiology, Vomiting, Pancreatic serous cystadenoma, Anticoagulant, Back pain, Pharmacist, Estate (law), Coronary thrombosis, Guideline, Patient, Amazon (company), Sidney Kimmel Comprehensive Cancer Center, Risk, Swelling, Anemia, Disease, FACS, Nausea, Johns Hopkins, Research, Health, Death, Red, Education, Caregiver, Content, Birth control, Cancer, MD

PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE). Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer. Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2

Key Points: 
  • Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2
    Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • "Cancer is a strong risk factor for developing a blood clot, and thrombosis is the second leading cause of death in patients with cancer.
  • Preventing and treating blood clots is also discussed in several relevant disease-specific NCCN patient guidelines, including for pancreatic cancer, multiple myeloma, and myeloproliferative neoplasms.

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

Retrieved on: 
Wednesday, September 6, 2023
Vitamins, Supplements, Insurance, Health Technology, Professional Services, Biotechnology, Managed Care, Health, General Health, Oncology, Survivor, DNA, Policy, Cancer, Geisinger Health System, National Comprehensive Cancer Network, GH, MRD, Medicare, Helmy Eltoukhy, Journal of the National Comprehensive Cancer Network, HIV disease progression rates, Patient, Colorectal cancer, Blood, Neoplasm, Recurrence, III, Disease, Pharmaceutical industry

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test.

Key Points: 
  • Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test.
  • “We are pleased that Geisinger Health Plan has taken this important step to make blood testing for residual disease more accessible to its members,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • The Geisinger Health Plan provides coverage for more than half a million members.
  • This policy decision adds to the payor coverage of Guardant Reveal, which received Medicare coverage in August 2022 and additional commercial payor coverage in July 2023.